Natural Products as Potential Human Ether-A-Go-Go-Related Gene Channel Inhibitors – Screening of Plant-Derived Alkaloids

Abstract

Inhibition of the cardiac human ether-a-go-go-related gene channel is a problematic off-target pharmacological activity and, hence, a major safety liability in clinical practice. Several non-cardiac drugs have been restricted in their use, or even removed from the market due to this potentially fatal adverse effect. Comparatively little is known about the human ether-a-go-go-related gene inhibitory potential of plant-derived compounds. In the course of an ongoing human ether-a-go-go-related gene in vitro study, a total of 32 structurally diverse alkaloids of plant origin as well as two semi-synthetically obtained protoberberine derivatives were screened by means of an automated Xenopus oocyte assay. Protopine, (+)-bulbocapnine, (+)-N-methyllaurotetanine, (+)-boldine, (+)-chelidonine, (+)-corynoline, reserpine, and yohimbine reduced the human ether-a-go-go-related gene current by ≥ 50 % at 100 µM, and were submitted to concentration-response experiments. Our data show that some widely occurring plant-derived alkaloids carry a potential risk for human ether-a-go-go-related gene toxicity.

Key words

natural products - hERG channel inhibition - Xenopus oocyte assay - plant-derived alkaloids - in vitro library screening

^* These authors contributed equally to this work.

• References

• 1 Laverty HG, Benson C, Cartwright EJ, Cross MJ, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park BK, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders PGA, Wallis R, Weaver R, York M, Valentin JP. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. Br J Pharmacol 2011; 163: 675-693
• 2 Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. HERG K⁺ channels: Structure, function, and clinical significance. Physiol Rev 2012; 92: 1393-1478
• 3 Kaczorowski GJ, Garcia ML, Bode J, Hess SD, Patel UA. The importance of being profiled: Improving drug candidate safety and efficacy using ion channel profiling. Front Pharmacol 2011; 2: 78
• 4 Li GR, Wang HB, Qin GW, Jin MW, Tang Q, Sun HY, Du XL, Deng XL, Zhang XH, Chen JB, Chen L, Xu XH, Cheng LC, Chiu SW, Tse HF, Vanhoutte PM, Lau CP. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation 2008; 117: 2449-2457
• 5 Zitron E, Scholz E, Owen RW, Lück S, Kiesecker C, Thomas D, Kathöfer S, Niroomand F, Kiehn J, Kreye VAW, Katus HA, Schoels W, Karle CA. QTc prolongation by grapefruit juice and its potential pharmacological basis: hERG channel blockade by flavonoids. Circulation 2005; 111: 835-838
• 6 Liu Y, Xu XH, Liu Z, Du XL, Chen KH, Xin X, Jin ZD, Shen JZ, Hu Y, Li GR, Jin MW. Effects of the natural flavone trimethylapigenin on cardiac potassium currents. Biochem Pharmacol 2012; 84: 498-506
• 7 Chen WH, Wang WY, Zhang J, Yang D, Wang YP. State-dependent blockade of human ether-a-go-go-related gene (hERG) K⁺ channels by changrolin in stably transfected HEK293 cells. Acta Pharmacol Sin 2010; 31: 915-922
• 8 Zhao J, Lian Y, Lu CF, Jing L, Yuan HT, Peng SQ. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on hERG potassium channels. J Ethnopharmacol 2012; 141: 685-691
• 9 Jeong I, Choi BH, Hahn SJ. Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5. Pflugers Arch 2010; 460: 851-862
• 10 Schramm A, Baburin I, Hering S, Hamburger M. hERG channel inhibitors in extracts of Coptidis rhizoma. Planta Med 2011; 77: 692-697
• 11 Schramm A, Jähne EA, Baburin I, Hering S, Hamburger M. Natural products as potential hERG channel inhibitors: Outcomes from a screening of widely used herbal medicines and edible plants. Planta Med in press
• 12 Khom S, Strommer B, Schöffmann A, Hintersteiner J, Baburin I, Erker T, Schwarz T, Schwarzer C, Zaugg J, Hamburger M, Hering S. GABA_A receptor modulation by piperine and a non-TRPV1 activating derivative. Biochem Pharmacol 2013; 85: 1827-1836
• 13 Kim YJ, Hong HK, Lee HS, Moh SH, Park JC, Jo SH, Choe H. Papaverine, a vasodilator, blocks the pore of the hERG channel at submicromolar concentration. J Cardiovasc Pharmacol 2008; 52: 485-493
• 14 Kim CS, Lee N, Son SJ, Lee KS, Kim HS, Kwak YG, Chae SW, Lee S, Jeon BH, Park JB. Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed hERG currents in Xenopus oocytes. Acta Pharmacol Sin 2007; 28: 503-510
• 15 Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. HERG-Lite®: A novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 2005; 52: 136-145
• 16 Witchel HJ, Milnes JT, Mitcheson JS, Hancox JC. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using hERG K⁺ channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 2002; 48: 65-80
• 17 Xia MH, Shahane SA, Huang RL, Titus SA, Shum E, Zhao Y, Southall N, Zheng W, Witt KL, Tice RR, Austin CP. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol Appl Pharmacol 2011; 252: 250-258
• 18 Vigneault P, Bourgault S, Kaddar N, Caillier B, Pilote S, Patoine D, Simard C, Drolet B. Galantamine (Reminyl®) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the hERG current. Eur J Pharmacol 2012; 681: 68-74
• 19 Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M, Hering S. State dependent dissociation of hERG channel inhibitors. Br J Pharmacol 2007; 151: 1368-1376
• 20 Rolland A, Fleurentin J, Lanhers MC, Younos C, Misslin R, Mortier F, Pelt JM. Behavioural effects of the American traditional plant Eschscholzia californica: Sedative and anxiolytic properties. Planta Med 1991; 57: 212-216
• 21 Song LS, Ren GJ, Chen ZL, Chen ZH, Zhou ZN, Cheng HP. Electrophysiological effects of protopine in cardiac myocytes: Inhibition of multiple cation channel currents. Br J Pharmacol 2000; 129: 893-900
• 22 Grabher P, Durieu E, Kouloura E, Halabalaki M, Skaltsounis LA, Meijer L, Hamburger M, Potterat O. Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts. Planta Med 2012; 78: 951-956
• 23 Cahlíková L, Macáková K, Kuneš J, Kurfürst M, Opletal L, Cvačka J, Chlebek J, Blunden G. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Eschscholzia californica (Papaveraceae). Nat Prod Commun 2010; 5: 1035-1038
• 24 Chlebek J, Macáková K, Cahlíková L, Kurfürst M, Kuneš J, Opletal L. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava (Fumariaceae). Nat Prod Commun 2011; 6: 607-610
• 25 Kulhánková A, Cahlíková L, Novák Z, Macáková K, Kuneš J, Opletal L. Alkaloids from Zephyranthes robusta BAKER and their acetylcholinesterase- and butyrylcholinesterase-inhibitory activity. Chem Biodivers 2013; 10: 1120-1127
• 26 Hoessel R, Leclerc S, Endicott JA, Nobel MEM, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1: 60-67
• 27 Friedländer P, Roschdestwensky N. Über ein Oxidationsprodukt des Indigoblaus. Ber Dtsch Chem Ges 1915; 48: 1841-1847
• 28 Dostál J, Potáček M, Man S, Humpa O. Non-aromatic derivatives of berberine. Scr Med (Brno) 1999; 72: 3-8
• 29 Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes for drug screening. Pflugers Arch 2006; 453: 117-123